{"disease":{"id":"myasthenia-gravis-crisis","name":"myasthenia gravis crisis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06617741","title":"Myasthenia Gravis Foundation of America Global MG Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3800,"lead_sponsor_name":"Myasthenia Gravis Foundation of America","has_results":false},{"nct_id":"NCT04837625","title":"Study of Myasthenic Crisis in China","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04674605","title":"A Prospective Cohort Study Of Myasthenia Gravis","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05214612","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06860633","title":"Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06688253","title":"Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}